Logo

Celltrion to Supply Herzuma (biosimilar- trastuzumab) and Truxima (biosimilar- rituximab) in Brazil

Share this
Celltrion to Supply Herzuma (biosimilar- trastuzumab) and Truxima (biosimilar- rituximab) in Brazil

Celltrion to Supply Herzuma (biosimilar- trastuzumab) and Truxima (biosimilar- rituximab) in Brazil

Shots:

  • The company has signed a supply agreement for 2 anticancer biosimilars- Herzuma (trastuzumab) and Truxima (rituximab) in Brazil. The supply of Herzuma accounts for ~80% of Brazil's trastuzumab market
  • Additionally- the company also won orders from eight state governments in Brazil for Truxima- including a bid in Sao Paulo. Following this- the company plans to expand its presence in Latin America
  • In March 2021- the company has initiated direct sales of infliximab biosimilar in Colombia and plans for rituximab and trastuzumab biosimilars in June & July respectively. The company also plans to expand its sales in Peru and Chile in Q3’21

 to   | Ref: Celltrion | Image: Pulse News Korea

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions